Axon Enterprise, Inc $AXON Shares Purchased by Forsta AP Fonden

Forsta AP Fonden increased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 35.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,300 shares of the biotechnology company’s stock after buying an additional 5,300 shares during the quarter. Forsta AP Fonden’s holdings in Axon Enterprise were worth $16,807,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AXON. Brighton Jones LLC purchased a new stake in shares of Axon Enterprise in the 4th quarter valued at $480,000. CWM LLC lifted its position in Axon Enterprise by 3.2% during the first quarter. CWM LLC now owns 4,713 shares of the biotechnology company’s stock valued at $2,479,000 after purchasing an additional 147 shares during the period. Signaturefd LLC boosted its holdings in Axon Enterprise by 10.4% in the first quarter. Signaturefd LLC now owns 838 shares of the biotechnology company’s stock valued at $441,000 after purchasing an additional 79 shares during the last quarter. Sigma Planning Corp boosted its holdings in Axon Enterprise by 50.3% in the first quarter. Sigma Planning Corp now owns 2,472 shares of the biotechnology company’s stock valued at $1,300,000 after purchasing an additional 827 shares during the last quarter. Finally, Apollon Wealth Management LLC grew its position in Axon Enterprise by 63.0% during the 1st quarter. Apollon Wealth Management LLC now owns 2,018 shares of the biotechnology company’s stock worth $1,061,000 after purchasing an additional 780 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the transaction, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the completion of the sale, the chief executive officer owned 3,043,982 shares in the company, valued at approximately $2,263,626,774.48. This trade represents a 0.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 52,041 shares of company stock valued at $36,794,077 in the last three months. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Down 0.5%

Shares of AXON opened at $569.51 on Thursday. The firm has a market cap of $44.94 billion, a P/E ratio of 140.62, a PEG ratio of 29.49 and a beta of 1.45. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The stock’s 50 day moving average is $709.82 and its two-hundred day moving average is $735.72. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter last year, the business earned $1.45 EPS. The company’s quarterly revenue was up 30.6% on a year-over-year basis. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. JMP Securities reissued a “market outperform” rating and issued a $825.00 price target on shares of Axon Enterprise in a report on Monday, September 29th. Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a research report on Tuesday, August 5th. Raymond James Financial reaffirmed an “outperform” rating and set a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Piper Sandler decreased their target price on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $810.71.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.